LDL‐cholesterol versus HDL‐cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos

Atherosclerosis is a complex disease in which many processes contribute to lesion development. Yet, it is well accepted that high serum levels of low‐density lipoproteins (LDL) play a main role in the initiation and progression of atherosclerosis. Despite currently available optimal LDL‐lowering therapies, a worrisome number of clinical events still occur. The protective effect of high‐density lipoproteins (HDL) in atherosclerosis, either by suppressing vascular‐LDL accumulation, inflammation, oxidation, endothelial damage, and thrombosis, has supported the need of the use of HDL‐raising therapies to address this residual risk. Results obtained in some studies, however, have shown that HDL quality, rather than quantity, should be the target of future pharmacological therapies. Here, we will first explore the mechanism by which excess LDL is fundamental in the development of atherosclerosis and its thrombotic complications, behaving as a factor that introduces chaos in the vascular wall. Afterwards, we will explore how functional HDL, through various cellular and molecular mechanisms, facilitates the resolution of this vascular chaos by suppression of atherosclerosis progression and induction of regression.

[1]  J. Mehta,et al.  Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. , 1996, The Journal of laboratory and clinical medicine.

[2]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[3]  Gaochao Zhou,et al.  27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells* , 2001, The Journal of Biological Chemistry.

[4]  M. Brown,et al.  Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. , 1987, Circulation.

[5]  J. Akkerman,et al.  Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein , 2006, Pathophysiology of Haemostasis and Thrombosis.

[6]  L. Badimón,et al.  Low-Density Lipoprotein Upregulates Low-Density Lipoprotein Receptor-Related Protein Expression in Vascular Smooth Muscle Cells: Possible Involvement of Sterol Regulatory Element Binding Protein-2-Dependent Mechanism , 2002, Circulation.

[7]  L. Badimón,et al.  Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos? , 2010 .

[8]  P. Lesnik,et al.  Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  T. Lüscher,et al.  High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. , 2010, Current pharmaceutical design.

[10]  J. Mehta,et al.  Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Borén,et al.  Molecular Mechanism for Changes in Proteoglycan Binding on Compositional Changes of the Core and the Surface of Low-Density Lipoprotein–Containing Human Apolipoprotein B100 , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[13]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[14]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[15]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[16]  J. Medalie,et al.  Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  G. Norata,et al.  Emerging role of high density lipoproteins as a player in the immune system. , 2012, Atherosclerosis.

[18]  T. Kita,et al.  Identification of soluble forms of lectin-like oxidized LDL receptor-1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. Winter,et al.  Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure , 2009, Journal of cardiovascular pharmacology.

[20]  T. Kodama,et al.  Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. , 2001, Journal of atherosclerosis and thrombosis.

[21]  J. Badimón,et al.  Plaque progression and regression in atherothrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[22]  J. Badimón,et al.  The role of high-density lipoprotein cholesterol in atherothrombosis. , 2006, The Mount Sinai journal of medicine, New York.

[23]  J. Badimón,et al.  The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. , 2006, Current molecular medicine.

[24]  V. Fuster,et al.  Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.

[25]  M. Ezekowitz,et al.  High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.

[26]  D. Shih,et al.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[27]  L. Wilkins Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE , 1979, Circulation.

[28]  L. Badimón,et al.  Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells , 2004, Circulation.

[29]  S. Kaul,et al.  Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. , 1999, The American journal of cardiology.

[30]  J. Gamble,et al.  Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. , 2001, Atherosclerosis.

[31]  L. Badimón,et al.  Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. , 1998, European journal of biochemistry.

[32]  M. Hayden,et al.  Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.

[33]  M. Aviram,et al.  Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. , 2000, Circulation.

[34]  P. Deedwania,et al.  Low high-density lipoprotein cholesterol: current status and future strategies for management , 2010, Vascular health and risk management.

[35]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[36]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[37]  M. Connelly,et al.  Scavenger receptor BI and cholesterol trafficking. , 1999, Current opinion in lipidology.

[38]  P. Barter,et al.  Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells , 2002, Current opinion in lipidology.

[39]  G. Vilahur,et al.  Lipoproteins, platelets and atherothrombosis. , 2009, Revista espanola de cardiologia.

[40]  V. Fuster,et al.  Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano , 2008, Journal of cellular and molecular medicine.

[41]  K. Saku,et al.  Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. , 1985, Thrombosis research.

[42]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[43]  H. Sinzinger,et al.  Hyperalphalipoproteinemia and prostaglandin I2 stability. , 1997, Thrombosis research.

[44]  LinaBadimon,et al.  LDL Receptor–Related Protein Mediates Uptake of Aggregated LDL in Human Vascular Smooth Muscle Cells , 2000 .

[45]  M. Mims,et al.  Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. , 1991, Journal of lipid research.

[46]  L. Badimón,et al.  Regulatory effects of HDL on smooth muscle cell prostacyclin release. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[47]  A. von Eckardstein,et al.  Implications of emerging risk factors for therapeutic intervention. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[48]  V. Fuster,et al.  High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[49]  A. Evans,et al.  High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. , 2002, Atherosclerosis.

[50]  A. Tward,et al.  Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.

[51]  S. Ylä-Herttuala Oxidized LDL and atherogenesis. , 1999, Annals of the New York Academy of Sciences.

[52]  D. Gordon,et al.  High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .

[53]  D. Haskard,et al.  Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1–Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation , 2001, Circulation.

[54]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[55]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[56]  V. Fuster,et al.  Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. , 1999, Circulation.

[57]  P. Subbaiah,et al.  Effects of Apolipoprotein A-I on ATP-binding Cassette Transporter A1-mediated Efflux of Macrophage Phospholipid and Cholesterol , 2003, Journal of Biological Chemistry.

[58]  P. Edwards,et al.  Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Assmann,et al.  High Density Lipoproteins Enhance the Na+/H+ Antiport in Human Platelets , 1996, Thrombosis and Haemostasis.

[60]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[61]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[62]  V. Fuster,et al.  Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). , 2012, Atherosclerosis.

[63]  A. von Eckardstein,et al.  Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids* , 2001, The Journal of Biological Chemistry.

[64]  A. Gotto,et al.  HDL Cholesterol and Protective Factors in Atherosclerosis , 2004, Circulation.

[65]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[66]  Sonia S Anand,et al.  Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. , 2003, JAMA.

[67]  A. Keys,et al.  Seven countries. A multivariate analysis of death and coronary heart disease. , 1980 .

[68]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[69]  L. Badimón,et al.  Experimental and interventional dietary study in humans on the role of HDL fatty acid composition in PGI2 release and Cox‐2 expression by VSMC , 2003, European journal of clinical investigation.

[70]  D. Norenberg Lipid Research Clinics Program , 1984 .

[71]  L. Badimón,et al.  Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. , 2007, Cardiovascular research.

[72]  L. Badimón,et al.  Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages Published, JLR Papers in Press, July 9, 2007. , 2007, Journal of Lipid Research.

[73]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[74]  Lina Badimon,et al.  LDL receptor-related protein and the vascular wall: implications for atherothrombosis. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[75]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[76]  L. Badimón,et al.  LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[77]  H. Lindmark,et al.  Inhibitory effects of N‐acetylcysteine on scavenger receptor class A expression in human macrophages , 2002, Journal of internal medicine.

[78]  L. Badimón,et al.  Intracellular lipid accumulation, low‐density lipoprotein receptor‐related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries , 2004, European journal of clinical investigation.

[79]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[80]  L. Badimón,et al.  Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. , 2008, Cardiovascular research.

[81]  C. McNamara,et al.  Role of smooth muscle cells in the initiation and early progression of atherosclerosis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[82]  Peter Libby,et al.  Effect of two intensive statin regimens on progression of coronary disease. , 2011, The New England journal of medicine.

[83]  G. Vilahur,et al.  Update on lipids, inflammation and atherothrombosis , 2011, Thrombosis and Haemostasis.

[84]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[85]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[86]  José A Fernández,et al.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.

[87]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[88]  A. Rigotti,et al.  Influence of the HDL Receptor SR-BI on Lipoprotein Metabolism and Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[89]  L. Malerød,et al.  Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. , 2002, Biochemical and biophysical research communications.

[90]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[91]  C. Sirtori,et al.  Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. , 1985, Biochemical medicine.

[92]  R. Epand,et al.  HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[93]  Iftikhar J Kullo,et al.  Conditional risk factors for atherosclerosis. , 2005, Mayo Clinic proceedings.

[94]  L. Badimón,et al.  Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin , 2009, Thrombosis and Haemostasis.

[95]  P. Barter Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. , 2009, The American journal of cardiology.

[96]  J. Badimón,et al.  HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[97]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[98]  L. Badimón,et al.  Cell biology and lipoproteins in atherosclerosis. , 2006, Current molecular medicine.

[99]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[100]  L. Badimón,et al.  Low-Density Lipoproteins Induce Heat Shock Protein 27 Dephosphorylation, Oligomerization, and Subcellular Relocalization in Human Vascular Smooth Muscle Cells , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[101]  L. Badimón,et al.  Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. , 2007, Cardiovascular research.

[102]  Allen J. Taylor,et al.  The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.

[103]  L. Badimón,et al.  Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.

[104]  Gemma Vilahur,et al.  Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.

[105]  Roger A. Renfrew,et al.  Lipid Research Clinics Program. , 1984, JAMA.

[106]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.